Genitourinary Cancer

Latest News

Enzalutamide Improves Undetectable PSA Levels in Nonmetastatic CSPC
Enzalutamide Improves Undetectable PSA Levels in Nonmetastatic CSPC

May 17th 2024

Enzalutamide with and without leuprolide improves rates of undetectable PSA levels compared with leuprolide alone in castration-sensitive prostate cancer.

Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer

April 20th 2024

Radiation Method Has ‘Excellent Oncological Outcomes’ in RCC
Radiation Method Has ‘Excellent Oncological Outcomes’ in RCC

March 28th 2024

Maintenance Avelumab Has Similar Efficacy in Real World for Urothelial Cancer
Maintenance Avelumab Has Similar Efficacy in Real World for Urothelial Cancer

March 5th 2024

Career Development
The Transition from Being an Oncology Nurse in Breast Cancer to an Advanced Practice Nurse in GU Oncology

January 3rd 2024

Latest CME Events & Activities

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

More News

© 2024 MJH Life Sciences

All rights reserved.